Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Next Previous
X
Search
Trial Profile

A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Travoprost (Primary) ; Bimatoprost
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Ocular Therapeutix

    • Most Recent Events

    • 06 Apr 2024 According to Ocular Therapeutics media release, positive data from PAXTRAVA 26 ug treatment arm presented at 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.
    • 06 Apr 2024 According to Ocular Therapeutics media release, due to elevations in IOP observed in seven out of the 16 subjects enrolled in the PAXTRAVA 5 µg arm of the trial, the company closed enrollment in this arm and continued with the PAXTRAVA 26 ug and DURYSTA arms of the trial.
    • 06 Apr 2024 Primary endpoint (Efficacy Outcome: IOP changes from Baseline(26 ug dose)) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top